Contribution of the central dopaminergic system in the anti-hypertensive effect of kinin B1 receptor antagonists in two rat models of hypertension

Neuropeptides

Volumn 44, Issue 2, 2010, Pages 191-198

  De Brito Gariepy, H ^a   Carayon, P ^b   Ferrari, B ^b   Couture, R ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b SANOFI   (France)

Author keywords

Blood pressure; Cardiovascular effect; Dopamine; Kinin B1R antagonist

Indexed keywords

ANGIOTENSIN II; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; HALOPERIDOL; RACLOPRIDE; SSR 240612; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ANTAGONISM; DRUG EFFICACY; DRUG RECEPTOR BINDING; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; BRAIN; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALOPERIDOL; HYPERTENSION; MALE; RACLOPRIDE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, BRADYKININ B1;

ANIMALIA; RATTUS;

EID: 77049111775     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2009.12.011     Document Type: Article

References (41)

1. Alvarez A.L., Delorenzi A., Santajuliana D., Finkielman S., Nahmod V.E., and Pirola C.J. Central bradykininergic system in normotensive and hypertensive rats. Clin. Sci. 82 (1992) 513-519
2. Amenta F., Ricci A., Rossodivita I., Avola R., and Tayebati S.K. The dopaminergic system in hypertension. Clin. Exp. Hypertens. 23 (2001) 15-24
3. Backhouse B., Barochovsky O., Malik C., Patel A.J., and Lewis P.D. Effects of haloperidol on cell proliferation in the early postnatal rat brain. Neuropathol. Appl. Neurobiol. 8 (1982) 109-116
4. Bader M., Bohnemeier H., Zollmann F.S., Lockley-Jones O.E., and Ganten D. Transgenic animals in cardiovascular disease research. Exp. Physiol. 85 (2000) 713-731
5. Cayla C., Merino V.F., Cabrini D.A., Silva Jr. J.A., Pesquero J.B., and Bader M. Structure of the mammalian kinin receptor gene locus. Int. Immunopharmacol. 2 (2002) 1721-1727
6. Cloutier F., de Sousa Buck H., Ongali B., and Couture R. Pharmacologic and autoradiographic evidence for an up-regulation of kinin B(2) receptors in the spinal cord of spontaneously hypertensive rats. Br. J. Pharmacol. 135 (2002) 1641-1654
7. Cloutier F., Ongali B., Campos M.M., Thibault G., Neugebauer W., and Couture R. Correlation between brain bradykinin receptor binding sites and cardiovascular function in young and adult spontaneously hypertensive rats. Br. J. Pharmacol. 142 (2004) 285-296
8. Couture R., and Girolami J.P. Putative roles of kinin receptors in the therapeutic effects of angiotensin 1-converting enzyme inhibitors in diabetes mellitus. Eur. J. Pharmacol. 500 (2004) 467-485
9. Couture R., and Lindsey C.J. Brain kallikrein-kinin system: from receptors to neuronal pathways and physiological functions. In: Quirion R., Björklund A., and Hökfelt T. (Eds). Hand. Chem. Neuroanat. vol. 16: Peptide Receptors, Part 1 (2000), Elsevier Science B.V. 241-300
10. De Brito Pereira, H., Couture, R., 2007. Brain tachykinin NK-3 receptors contribute to arterial hypertension through a dopaminergic mechanism. In: 38th Annual Meeting of Society for Neuroscience, November 3-7, San Diego, CA, USA, 2007 (P296.12).
11. De Brito Pereira, H., Talbot, S., Ongali, B., Couture, R., 2008. Role of kinin B1 receptor in the central autonomic control of blood pressure and body temperature in two rat models of hypertension. In: 39th Annual Meeting of the Society for Neuroscience, November 12-15, Washington, DC, USA, 2008 (P83.18).
12. De Wardener H.E. The hypothalamus and hypertension. Physiol. Rev. 81 (2001) 1599-1658
13. Deschamps K., and Couture R. The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation. Br. J. Pharmacol. 145 (2005) 712-727
14. Dias J.P., Ismael M.A., Pilon M., de Champlain J., Ferrari B., Carayon P., and Couture R. The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance. Br. J. Pharmacol. 152 (2007) 280-287
15. Dias, J.P., Talbot, S., Pilon, M., Sénécal, J., de Champlain, J., Ferrari, B., Carayon, P., Couture, R., 2009. Kinin B1 receptor as a therapeutic target in the treatment of diabetes. In: The Fifth International Symposium on Peptide Receptors and Kinin 2009, June 26-30, Quebec, Canada (P28).
16. 1 receptor and the central regulation of blood pressure in spontaneously hypertensive rats. Br. J. Pharmacol. 126 (1999) 1769-1776
17. Gougat J., Ferrari B., Sarran L., Planchenault C., Poncelet M., Maruani J., Alonso R., Cudennec A., Croci T., Guagnini F., Urban-Szabo K., Martinolle J.P., Soubrié P., Finance O., and Le Fur G.J. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 309 (2004) 661-669
18. Hashimoto K., and Ishiwata K. Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. Curr. Pharm. Des. 12 (2006) 3857-3876
19. Ismael M.A., Talbot S., Carbonneau C.L., Beauséjour C.M., and Couture R. Blockade of sensory abnormalities and kinin B1 receptor expression by N-acetyl-l-cysteine and ramipril in a rat model of insulin resistance. Eur. J. Pharmacol. 589 (2008) 66-72
20. Jose P.A., Eisner G.M., and Felder R.A. Role of dopamine in the pathogenesis of hypertension. Clin. Exp. Pharmacol. Physiol. Suppl. 26 (1999) 10-13
21. Khan I.M., Yamaji I., Miller D.H., Margolius H.S., and Privitera P.J. Cerebrospinal fluid kallikrein in spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J. Hypertens. 11 (1993) 1039-1045
22. Khan I.M., Miller D.H., Strickland J., Margolius H.S., and Privitera P.J. Brain kallikrein-kinin system abnormalities in spontaneously hypertensive rats. Hypertension 25 (1995) 524-530
23. Kirouac G.J., and Ganguly P.K. Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis. Neuroscience 52 (1993) 135-141
24. Laplante M.A., Wu R., El Midaoui A., and de Champlain J. NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J. Hypertens. 21 (2003) 927-936
25. Leeb-Lundberg L.M., Marceau F., Müller-Esterl W., Pettibone D.J., and Zuraw B.L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57 (2005) 27-77
26. Lessard A., Campos M.M., Neugebauer W., and Couture R. Implication of nigral tachykinin NK3 receptors in the maintenance of hypertension in spontaneously hypertensive rats: a pharmacologic and autoradiographic study. Br. J. Pharmacol. 138 (2003) 554-556
27. Lessard A., Laurin M., Yamaguchi N., and Couture R. Central anti-hypertensive effect of tachykinin NK3 receptor antagonists in rat. Eur. J. Pharmacol. 486 (2004) 75-83
28. Lin M.T., and Yang J.J. Stimulation of the nigrostriatal dopamine system produces hypertension and tachycardia in rats. Am. J. Physiol. 266 (1994) H2489-2496
29. Linthorst A.C., van Giersbergen P.L., Gras M., Versteeg D.H., and de Jong W. The nigrostriatal dopamine system: role in the development of hypertension in spontaneously hypertensive rats. Brain Res. 639 (1994) 261-268
30. Lungu C., Dias J.P., França C.E., Ongali B., Regoli D., Moldovan F., and Couture R. Involvement of kinin B1 receptor and oxidative stress in sensory abnormalities and arterial hypertension in an experimental rat model of insulin resistance. Neuropeptides 41 (2007) 375-387
31. Martins D.T.O., Fior D.R., Nakaie C.R., and Lindsey C.J. Kinin receptors of the central nervous system of spontaneously hypertensive rats related to the pressor response to bradykinin. Br. J. Pharmacol. 103 (1991) 1851-1856
32. 4 receptors: an in vitro and in vivo comparison with L 745, 870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. J. Pharmacol. Exp. Ther. 287 (1998) 167-186
33. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10 (2005) 79-104
34. Ongali B., Buck H.d.S., Cloutier F., Legault F., Regoli D., Lambert C., Thibault G., and Couture R. Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord. Am. J. Physiol. Heart Circ. Physiol. 284 (2003) H1949-1958
35. Petcu M., Ongali B., El Midaoui A., de Champlain J., and Couture R. Effects of alpha-lipoic acid on kinin B1 and B2 receptor binding sites in the spinal cord of chronically angiotensin-treated rats. Peptides 26 (2005) 1331-1338
36. Qadri F., Hauser W., Johren O., and Dominiak P. Kinin B1 and B2 receptor mRNA expression in the hypothalamus of spontaneously hypertensive rats. Can. J. Physiol. Pharmacol. 80 (2002) 258-263
37. Regoli D., Rizzi A., Perron S.I., and Gobeil Jr. F. Classification of kinin receptors. Biol. Chem. 382 (2001) 31-35
38. Rodi D., Couture R., Ongali B., and Simonato M. Targeting kinin receptors for the treatment of neurological diseases. Curr. Pharm. Des. 11 (2005) 1313-1326
39. van den Buuse M. Pressor responses to brain dopaminergic stimulation. Clin. Exp. Pharmacol. Physiol. 24 (1997) 764-769
40. van den Buuse M., Linthorst A.C., Versteeg D.H., and de Jong W. Role of brain dopamine systems in the development of hypertension in the spontaneously hypertensive rats. Clin. Exp. Hypertens. A 13 (1991) 653-659
41. Vaughan C.E., van den Buuse M., and Roland B.L. Brain dopamine D2 receptor mRNA levels are elevated in young spontaneously hypertensive rats. Neurosci. Res. 34 (1999) 199-205